NCT06888050 Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study
| NCT ID | NCT06888050 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | New-onset Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 268 participants |
| Start Date | 2025-04-11 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 268 participants in total. It began in 2025-04-11 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter, randomized controlled trial aims to evaluate the efficacy and safety of Henagliflozin-Metformin Sustained-Release Tablets (I) versus Metformin Tablets in newly diagnosed type 2 diabetes mellitus (T2DM). A total of 268 participants will be randomized (1:1) into two groups: the experimental group receiving Henagliflozin-Metformin Sustained-Release Tablets (I) (5mg/500mg, once daily) with lifestyle intervention, and the control group receiving Metformin Tablets (500mg, twice daily) with lifestyle intervention. The primary outcome is the change in glycated hemoglobin (HbA1c) from baseline at 24 weeks. Secondary outcomes include changes in fasting/postprandial blood glucose, body weight, metabolic parameters, diabetes remission rate, and safety assessments. This trial will provide evidence for early combination therapy in newly diagnosed T2DM patients.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years old. * Diagnosed with type 2 diabetes according to WHO diagnostic criteria, with HbA1c between 7% and 9% at this examination, fasting venous blood glucose ≤ 11.1 mmol/L, and BMI ≥ 18.5 kg/m2; known disease duration ≤ 24 months. * Voluntary participation in this study and signing of the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must be present to observe the informed consent process and sign the informed consent form on their behalf. * No previous use of hypoglycemic drugs. Exclusion Criteria: * Type 1 diabetes. * Participants who have participated in other clinical trials of diabetes treatment drugs before the start of this study. * Those who have experienced diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non-ketotic coma within the past six months and required hospitalization. * Those who have experienced decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past six months. * Those taking glucocorticoid drugs (excluding topical or inhaled medications). * Those with a life expectancy of less than one year due to malignant tumors, active tuberculosis, or acute infections. * Those with clinically significant urinary tract or genital infections, or a history of recurrent urinary tract or genital infections. * Those with a history of hypertension whose blood pressure has not been effectively controlled despite antihypertensive drug treatment: systolic blood pressure (SBP) \> 160 mmHg and/or diastolic blood pressure (DBP) \> 100 mmHg. * Those with liver and kidney function indicators meeting the following criteria: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 3.0×ULN; estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² (calculated according to the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula). * Those allergic to the investigational drug or its components. * Pregnant or lactating women and those with the intention to conceive within three months of the last dose. * Other patients deemed unsuitable for participation in this clinical trial by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06888050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying New-onset Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06888050 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06888050 currently recruiting?
Yes, NCT06888050 is actively recruiting participants. Contact the research team at drxhwu@163.com for enrollment information.
Where is the NCT06888050 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06888050 clinical trial?
NCT06888050 is sponsored by Zhejiang Provincial People's Hospital. The trial plans to enroll 268 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.